Von Eschenbach attacked from both sides
This article was originally published in The Gray Sheet
Executive Summary
Conservatives, including Concerned Women for America and the National Pro-Life Action Center, call for the withdrawal of FDA Acting Commissioner Andrew von Eschenbach's nomination to head the agency in reaction to FDA signals that it might be moving toward approving over-the-counter status for Barr Pharmaceutical's Plan B emergency contraceptive. The firm plans to resubmit its OTC application by the end of the month after an Aug. 8 meeting with the agency. Meanwhile, Sens. Hilary Clinton (D-N.Y.) and Patty Murray (D-Wash.), who support the OTC switch, said July 31 they will maintain their hold on von Eschenbach's nomination until the agency makes a decision (1"The Gray Sheet" Aug. 7, 2006, p. 17)...